top of page
Group 1261.png

RLL's Story begins...

with a molecule essential to the health of all living cells. That molecule is called Proliferating Cell Nuclear Antigen or PCNA.

The PCNA Story

To promote cell division, PCNA acts as a circular clamp, surrounding the DNA molecule, guiding the replication process.

PCNA is a critical ‘hub’ to many vital cellular processes: Over 200 key molecules bind to the PCNA clamp and are essential for normal cellular repair and replication.

image4.png

How AOH1996 Works

In 1998, Dr. Malkas’ team discovered an isoform of PCNA (“ca-PCNA”) that is uniquely present and stable only in cancer cells.

 

RLL’s revolutionary therapeutic drug, AOH1996, binds specifically to the unique structure of ca-PCNA, inhibiting cancer cell replication and leading to cancer cell death via apoptosis. 

Preclinical data has established that ca-PCNA acts on cancerous cells while having minimal to no effect on the replication of healthy cells.​

Group 1324b.png
RLLNEWLOGO.png

Included herein is information regarding RLL, LLC which may include, among other information, financial and/or scientific projections and prospects. Please note that the projections are based upon assumptions, some of which may change substantially before a confidential memorandum or other offering materials are prepared, some or all of which may not materialize. The information provided does not constitute any offer to sell or any solicitation of any offer to purchase any security, which offer will be made, if at all, only by a confidential memorandum or other offering materials prepared for such use and including applicable risk factors for the Company's offering and information regarding the securities laws of the applicable jurisdictions in which offers and sales are intended to occur.

© 2025 by RLL, LLC.

bottom of page